Tiny trial tests triple threat against brain tumors from kidney cancer
NCT ID NCT06132945
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether combining two cancer drugs (cabozantinib and nivolumab) with precise radiation is safe for people with kidney cancer that has spread to the brain. Only 2 participants were enrolled, and the main goal is to see if they can tolerate the treatment without serious brain-related side effects over 56 days. The researchers also track quality of life and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib (a targeted cancer drug) and nivolumab (an immunotherapy drug) combined with stereotactic radiosurgery (precise radiation)
What this could lead to
If this combination proves safe, it could point toward a new treatment option for kidney cancer that has spread to the brain.
What could go wrong
This is a very early, tiny Phase 1 trial with only 2 participants, so results may not apply to others. The main goal is just safety, not effectiveness, and there are risks of serious side effects from the drugs and radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States